What is Climb Bio, Inc.'s acquisitions?

Climb Bio, Inc. (CLYM) reported acquisitions of $0 in Q4 2025.

How has Climb Bio, Inc.'s acquisitions changed year-over-year?

Climb Bio, Inc.'s acquisitions decreased by 100.0% year-over-year, from $1.16M to $0.

Cash paid for business acquisitions net of cash acquired in the target company — the primary M&A cash flow line.

Bristol-Myers SquibbBMY

$65M-16.7%

Operating income-$15.2M+33.9%

Net income-$13.7M+34.0%

EPS (diluted)-$0.20+35.5%

Cash & equivalents$8.4M-71.2%

Total debt$479.0K+1.1%

Total equity$148.1M-23.4%

Total assets$152.4M-24.1%

Operating cash flow-$14.4M+6.8%

CapEx$109.0K—

Free cash flow-$15.6M-183%

Market cap$724.95M+787%

Enterprise value$717.07M+1,247%

Return on equity-30.9%-10.3pp

Debt / equity0×0.0×

Current ratio27.9×+13.6×

Reported directly by Climb Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired.

The official record: Climb Bio, Inc.’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Climb Bio, Inc.'s acquisitions?: Climb Bio, Inc. (CLYM) reported acquisitions of $0 in Q4 2025.
How has Climb Bio, Inc.'s acquisitions changed year-over-year?: Climb Bio, Inc.'s acquisitions decreased by 100.0% year-over-year, from $1.16M to $0.
What does acquisitions mean?: Cash paid for business acquisitions net of cash acquired in the target company — the primary M&A cash flow line.